Liver and spleen stiffness measurements in patients with BCR-ABL-negative myeloproliferative neoplasms and their clinical significance / 中国基层医药

Objective:To measure liver and spleen stiffness in patients with BCR-ABL-negative myeloproliferative neoplasms and analyze their clinical significance.Methods:Fifteen healthy volunteers and 27 patients with BCR-ABL-negative myeloproliferative neoplasms underwent liver and spleen thickness measurements using FibroScan 502 Touch medical device between June 2018 and June 2020 in Hebei Petro China Central Hospital and they were included in this study. Liver and spleen stiffness was correlated with clinical laboraty indicators.Results:Liver stiffness, spleen stiffness, and the difference between spleen stiffness and liver stiffness in patients with BCR-ABL-negative myeloproliferative neoplasms were significantly greater than those in healthy controls [(6.34 ± 2.22) kPa vs. (5.07 ± 1.27) kPa; (26.00 ± 10.66) kPa vs. (13.61 ± 5.64) kPa; (19.65 ± 10.37) kPa vs. (8.54 ± 5.33) kPa, t = -2.01, -4.30, -4.06, all P < 0.05]. Platelet count was negatively correlated with liver and spleen stiffness ( r = -0.39, -0.42). White blood cell count was negatively correlated with the difference between spleen stiffness and liver stiffness ( r = -0.40, P < 0.05). The uric acid level was negatively correlated with liver stiffness ( r = -0.54, P < 0.05), but it was positively correlated with spleen thickness ( r = 0.41, P < 0.05). The percentage of B lymphocytes among lymphocytes was negatively correlated with spleen stiffness and the difference between spleen stiffness and liver stiffness ( r= -0.56, -0.56, both P < 0.05). The percentage of diseased megakaryocytes was positively correlated with spleen stiffness ( r = 0.40, P < 0.05). The percentage of sideroblasts was negatively correlated with liver stiffness ( r = -0.44, P < 0.05). Conclusion:Spleen stiffness and liver stiffness are closely related to clinical indicators in patients with BCR-ABL-negative myeloproliferative neoplasms, including white blood cell count, platelet count, uric acid level, percentage of B lymphocytes, diseased megakaryocytes and sideroblasts. Dynamic monitoring of liver and spleen stiffnesses or in combination with bone marrow examination in future can help evaluate the condition of patients with BCR-ABL-negative myeloproliferative neoplasms.

Dépistage de la stéatose hépatique par le Fibroscan/CAP chez les sujets noirs africains porteurs d'une Hépatite Virale B chronique en Côte d'Ivoire / Fibroscan/CAP screening for hepatic steatosis in black African subjects with chronic Viral Hepatitis B in Ivory Coast

Context and objectives As the global epidemic of obesity and metabolic syndrome progresses, the coexistence of fatty liver disease in patients with chronic viral hepatitis B (VHB) becomes significant. The objective of this work was to determine the frequency of hepatic steatosis assessed by Fibroscan/CAP (Controlled Attenuation Parameter) in patients with chronic VHB in Côte d'Ivoire. Methods. The study included 83 patients with chronic VHB. These were black patients who had performed a Fibroscan/CAP during the recruitment period and were willing to participate in the study. Patients with significant alcohol consumption, a secondary cause of hepatic steatosis, another liver disease regardless of the etiology associated with VHB were not included. Results. The frequency of hepatic steatosis in chronic HBV carriers assessed by CAP in our study population was 48.19 %, including 24.10 % of severe steatosis. Obesity was statistically correlated with the presence of steatosis in our patients. Patients who had steatosis on ultrasound were 5 times more likely to have steatosis on CAP. Significant fibrosis was insignificantly associated with steatosis. Conclusion. The frequency of fatty liver disease detected by fibroscan/CAP is high in patients with chronic VHB.

Contexte et objectifs Avec la progression de l'épidémie mondiale d'obésité et du syndrome métabolique, la coexistence d'une stéatose hépatique chez les patients porteurs d'une hépatite virale B chronique devient non négligeable. L'objectif de ce travail était de déterminer la fréquence de la stéatose hépatique chez les patients porteurs d'une hépatite virale B (HVB) chronique. Méthodes. Il s'agissait d'une série des cas de HVB de race noire, ayant réalisé un Fibroscan/CAP pendant la période du recrutement et consentants à participer à l'étude. Les patients ayant une consommation d'alcool significative, une cause secondaire de stéatose hépatique, une autre hépatopathie quelle que soit l'étiologie associée à l'hépatite B n'ont pas été inclus. Résultats. Quatre-vingt-trois patients porteurs d'une HVB ont été inclus. La fréquence de la stéatose hépatique chez les porteurs du VHB chronique était de 48,19 % dont 24,10 % de stéatose sévère. L'obésité était statistiquement corrélée à la présence d'une stéatose chez nos patients. Les patients qui avaient une stéatose à l'échographie étaient 5 fois plus à risque d'avoir une stéatose au CAP. La fibrose significative était associée de façon non significative à la stéatose. Conclusion : Près de la moitié des patients porteurs d'une hépatite virale B chronique présente une stéatose hépatique.

Correlation of Transient Elastography With MRI T2* and Serum Ferritin Levels in Children With Transfusion-Dependent Thalassemia

Objectives: We investigated the correlation of transient elastography (TE) with MRI R2* values and serum ferritin in patients with transfusion-dependent thalassemia (TDT) Methods: We reviewed hospital records of 59 patients with TDT aged ?8 years without any evidence of chronic liver disease and who had fibroscan within 3 months of MRI T2*, who seen at our center between January, 2014 and December, 2019. Spearman correlation and linear regression analysis were used to evaluate the correlation between TE liver stiffness measurements and R2* MRI values and with serum ferritin. Results: Mean (SD) age of the subjects was 13.0 (3.1) years and body mass index was 16.6 (2.3) kg/m2. Mean liver stiffness measurement, MRI T2*(3T), corresponding MRI R2*(3T), and ferritin values were 6.55 (3.10) kPa, 3.4 (4.6) milliseconds, 616.20 (383.9) Hz, and 2874.69 (1570.7) ng/ mL, respectively. TE measurements correlated with MRI R2* values (r=0.61; P=0.001) and with serum ferritin level (r=0.59, P=0.001). Conclusion: TE is a reliable tool to estimate hepatic iron overload in patients with TDT.

Study to Find Out the Correlation Between Cognitive Defect and Non-alcoholic Fatty Liver Disease

Introduction : Non-alcoholic Fatty Liver Disease (NAFLD), a hepatic manifestation of Metabolic Syndrome, has now become a Global Phenomenon and along with its increasing prevalence various morbidities and mortality are also increasing. Aims and Objectives : The objective of the present study was to establish whether patients with NAFLD, in the absence of other comorbid conditions suffer from cognitive impairment. Materials and Methods : This cross sectional study was conducted at the Department of General Medicine, Calcutta National Medical College and Hospital. 90 patients with NAFLD and 90 healthy controls were recruited after matching all the inclusion and exclusion criteria, from the out patient and in patient department over a period of 1 year starting March, 2019. NAFLD was diagnosed by noninvasive methods including Elastography (fibroscan). Cognition was assessed by MoCA (Montreal Cognitive Assessment test) score. Result : The mean age of cases and control were 49.2 and 48.5 years, respectively. Out of total cases and controls 48.9% was male and 51.1% was female. The mean BMI of the cases and control were 30.21�24 and 22.60�52 Kg/m2, respectively. The mean Elastography score among the cases was 4.91�23 kPa and that among the controls was 3.84�31 kPa. The mean Fibroscan Score among male cases and controls were 4.907�26 kPa and 3.83�35, respectively (p

Assessment of chronic kidney disease in patients with non-alcoholic fatty liver disease (NAFLD); A single center experience

Background: Non-alcoholic fatty liver disease (NAFLD) represents a considerable percentage of chronic liver diseases worldwide. The liver is not the only organ affected by NAFLD but also affects other organs such as the cardiovascular system and the kidney. In recent decades, there has been a growing body of evidence linking NAFLD to kidney function. So, the current study aims to assess the percentage of chronic kidney disease (CKD) in NAFLD patients and its link to different stages of hepatic fibrosis. Patients and Methods: A case-control study evaluated 62 non-alcoholic fatty liver disease patients and a control group of 38 volunteers with apparently healthy livers (normal echo pattern by ultrasound). All participants underwent serum creatinine measurement, albumin creatinine ratio in urine, calculation of estimated glomerular filtration rate (eGFR), abdominal ultrasound, and fibroScan examination. Results: The authors showed that the percentage of patients with chronic kidney diseases (patients with GFR less than 60 ml or micro-albuminuria) were significantly higher among NAFLD groups than in healthy controls. There was a significant positive correlation between the albumin creatinine ratio and subcutaneous fat thickness, BMI, and steatosis degrees. The estimated glomerular filtration rate (eGFR) and the age of the patients had a significant negative correlation. In comparison, the eGFR and AST levels had a significant positive correlation. Conclusions: Our results showed that NAFLD substantially raises the risk of getting CKD

Fibrofast and fibrosis-4 versus fibroscan as indicators of hepatic fibrosis in non-alcoholic fatty liver disease patients: A cross sectional Study

Aims: Non-alcoholic fatty liver disease (NAFLD) is a broad category for a disease spectrum that includes simple steatosis, which can proceed to non-alcoholic steatohepatitis, cirrhosis, and, finally, hepatocellular carcinoma. Owing to the invasive nature of liver biopsy, the need for non-invasive tools were required for diagnosis. Objective: To compare the performance of simple biochemical scores (fibroblast) FIB-5 and (fibrosis-4) FIB-4 with fibroscan to differentiate mild to moderate fibrosis (MF; F0 to F2) from advanced fibrosis (AF; F3 to F4) in patients with NAFLD. Patients and methods: This cross-sectional study was done on 116 NAFLD patients. All patients were scanned with the FibroScan examination. FIB-5 and FIB-4 were calculated for all patients. Results: The mean kPa score (liver stiffness measurement score) of the patients belonging to advanced fibrosis [9.53 ± 1.05]. The FIB-4 score was significantly higher in patients with advanced fibrosis (1.54 ± 0.38) compared with patients with mild to moderate fibrosis (1.18 ± 0.44), p-value = 0.001, whereas the FIB-5 score was insignificant between patients. Conclusion: FIB-4 is superior to FIB-5 as a non-invasive simple marker in diagnosing advanced fibrosis in NAFLD patients.

Indirect serum biomarkers perform sub optimally in screening for significant liver fibrosis among HIV-infected and uninfected adults in Uganda

ntroduction: Indirect serum biomarkers present an acceptable noninvasive and cheap alternative for screening of significant liver fibrosis (SLF). Evaluation of their use in resource limited settings is important to determine their utility. Methods: We conducted a cross sectional study among 520 HIV infected and HIV uninfected adults attending care clinics in Kampala Uganda. Presence of SLF was determined using Fibroscan® liver stiffness measurement of ≥7.2KPa. The diagnostic value of indirect serum biomarkers for diagnosis of SLF was evaluated using the area under the receiver operating characteristics curve (AUROC) using Fibroscan® as gold standard. Results: Overall AUROC values for Age Platelet Index (API), Aspartate to Alanine Ratio (AAR), AST-to-Platelet Ratio Index (APRI), Fibrosis Index based on 4 Factors (FIB-4) and Gamma glutamyl transferase to Platelet Ratio Index (GPR) were 0.52, 0.49, 0.55, 0.55 and 0.54 respectively. Among HIV-infected participants AUROC values were slightly improved at predicting presence of SLF but still under 70%. Conclusion: Despite APRI and FIB-4 being more likely to identify participants with SLF, the overall diagnostic value of all serum biomarkers was poor with and without stratification by HIV status. We recommend the use of Fibroscan® technology as more accurate non-invasive diagnostic method for screening of SLF

Evaluación de la fibrogénesis hepática en pacientes con esteatohepatitis no alcohólica tratados con propóleos rojo oral cubano / Evaluation of hepatic fibrogenesis in patients with nonalcoholic steatohepatitis treated with cuban oral red propolis

Introducción: La enfermedad por depósito graso no alcohólica constituye una pandemia del mundo contemporáneo. Su espectro silente atraviesa estadios de cronicidad y puede llegar a la cirrosis hepática y sobre esta pudiera desarrollarse un hepatocarcinoma. No existen tratamientos y solo se puede actuar sobre los factores de riesgo. Objetivo: Evaluar el efecto citohepatoprotector y antifibrótico del propóleos rojo cubano oral en pacientes con esteatohepatitis no alcohólica. Métodos: Se realizó un estudio longitudinal prospectivo en pacientes seleccionados de las consultas de Gastroenterología, Endocrinología y Medicina Interna del Hospital Clínico Quirúrgico Hermanos Ameijeiras durante el periodo de abril 2017 a abril 2018. El universo de estudio fue de 120 pacientes con diagnóstico imagenológico de hígado graso. La muestra quedó conformada por 70 pacientes con diagnóstico de hígado graso, y que cumplieron criterios de inclusión y exclusión. Las pruebas estadísticas aplicadas fueron análisis de frecuencia y porcentaje para las variables demográficas. La prueba T para las muestras relacionadas evaluó el comportamiento enzimático al inicio y al final del tratamiento y los cambios elastográficos fueron analizados mediante test de Kappa y porcentaje. Resultados: Las variables bioquímicas estudiadas mostraron una disminución estadísticamente significativa al final del tratamiento. Los cambios elastográficos al final del estudio evidenciaron la efectividad del tratamiento, en el cual el 91,4 por ciento de los pacientes evolucionaron hacia el menor grado de fibrosis. Conclusiones: El propóleos rojo cubano demostró ser un apifármaco con acción citohepatoprotectora y antifibrótica de valor terapéutico(AU)

Introduction: Nonalcoholic fat deposition disease is a pandemic in the contemporary world. Its silent spectrum goes through stages of chronicity and it can reach liver cirrhosis and on this a hepatic carcinoma could develop. There are no treatments and medical handling can act on only risk factors. Objective: To evaluate cytohepatoprotective and antifibrotic effect of oral Cuban red propolis in patients with nonalcoholic steatohepatitis. Methods: A prospective longitudinal study was carried out in selected patients from the Gastroenterology, Endocrinology and Internal Medicine consultations at Hermanos Ameijeiras Clinical Surgical Hospital from April 2017 to April 2018. The study universe was 120 patients with imaging diagnosis of fatty liver. The sample consisted of 70 patients with fatty liver diagnosis, who met the inclusion and exclusion criteria. Frequency and percentage analysis for the demographic variables were the statistical tests applied. The T test for the related samples evaluated the enzymatic behavior at the beginning and at the end of the treatment and the elastography changes were analyzed using Kappa and percentage tests. Results: The biochemical variables studied showed statistically significant decrease at the end of the treatment, which evidenced the effectiveness of the treatment. 91.4 percent of the patients progressed to a lower degree of fibrosis. Conclusions: Cuban red propolis proved to be a therapeutic drug with cytohepathoprotective and antifibrotic action(AU)

Non-invasive markers for staging fibrosis in patients with chronic hepatitis Delta / Монголын Анагаах Ухаан

Introduction@#Determining stages of liver fibrosis in chronic liver disease is essential for clinical practice such as decision making on medical treatment, setting the interval of follow-up examination for its complication, screening intervals for hepatocellular carcinoma. @*Goal@#We compared non-invasive fibrosis markers among the patients with chronic hepatitis Delta. @*Materials and Methods@#Totally 70 patients with chronic hepatitis D enrolled into this study. The blood samples were examined for complete blood count, liver function test and serum M2BPGi level. Non-invasive markers such as AAR, APRI, Fib-4 scores were calculated. Those with AAR >1, APRI >0.7, FIB-4 >1.45 were considered with advanced fibrosis. All patients underwent liver stiffness measurement using FibroScan M2 probe. The cutoff values of FibroScan for advanced fibrosis were 9 kPa for patient with normal transaminase level and 11 kPa for patients with elevated transaminase. @*Results@#Advanced fibrosis was observed in 25.7%, 38.6% and 38.6% by AAR, APRI and Fib-4 score, respectively. When cut-off levels of serum M2BPGi for advanced fibrosis was 2.2 COI, 35.7% had advanced fibrosis. FibroScan tests showed 34.4% had advanced fibrosis. The AUROC of M2BPGi were 0.894 and 0.827 for predicting advanced fibrosis and liver cirrhosis. @*Conclusion@#Serum M2BPGi and FibroScan would be reliable diagnostic tool for identifying liver fibrosis in Mongolian patients with chronic hepatitis D.

Study on intervention effect of systematic nutrition combined with rhythmic exercise in patients with abnormal liver metabolism / 公共卫生与预防医学

Objective To study the intervention effect of systematic nutrition combined with rhythmic exercise on patients with abnormal liver metabolism. Methods According to the theory of system nutrition and health rhythm kinematics, selected 56 subjects with abnormal liver metabolism were selected, and the combined intervention of system nutrition and rhythm movement was conducted regularly every day for 3 consecutive months using the techniques such as liver transient elastography (FibroScan) and bioelectric whole body health scanning system (DDFAO). Results Compared with the pre-intervention period, the liver fat attenuation, liver hardness and liver functional activity of the subjects were significantly improved after intervention. Conclusion The systematic nutrition combined with rhythmic exercise significantly reduced the risk of abnormal liver metabolism in subjects, which may play an important role in preventing liver diseases and promoting the recovery of liver function.

Fibroscan como diagnóstico de hipertensión portal en pacientes cirróticos / Fibroscan as a diagnosis of portal hypertension in cirrhotic patients / Fibroscan como diagnóstico de hipertensão portal em pacientes cirróticos

Resumen: Introducción: La hipertensión portal es un síndrome frecuente en las hepatopatías crónicas. Entre sus etiologías destaca la cirrosis hepática, responsable en la gran mayoría de los casos. Desde la incorporación de la Elastografía de Transición (Fibroscan) en Uruguay, no se han realizado estudios a nivel nacional que relacionen los resultados obtenidos mediante esta técnica con la presencia de hipertensión portal en pacientes cirróticos. Objetivo: Caracterizar la población cirrótica diagnosticada mediante Fibroscan, atendida en la policlínica de Hepatología del Hospital Pasteur. Material y Métodos: Se estudiaron los pacientes con diagnóstico de cirrosis hepática de cualquier etiología asistidos y controlados en la policlínica de Hepatología del Hospital Pasteur en el periodo de 2015 a 2018. Resultados: Se incluyeron 49 pacientes, de los cuales 34 presentaban hipertensión portal. Se encontró mayor prevalencia de cirrosis hepática en hombres con etiología alcohólica y por infección por virus de la hepatitis C. Se halló asociación entre valores de ET ≥ 15 kPa y la presencia de hipertensión portal. No fue posible demostrar asociación estadísticamente significativa entre valores de ET ≥ 15 kPa y la presencia de várices esófago gástricas y/o gastropatía por hipertensión portal. Conclusiones: El punto de corte utilizado en el Fibroscan es útil para diagnóstico de hipertensión portal. Es necesario continuar realizando fibrogastroscopía para el diagnóstico de la misma.

Abstract: Introduction: Portal hypertension is a syndrome that is frequently present in chronic liver diseases. Within the causes that results in portal hypertension, liver cirrhosis outstands, being responsible for most cases. Since the incorporation of transient elastography (Fibroscan) in Uruguay, no research has been conducted at a national level that correlates the results obtained by Fibroscan with the presence of portal hypertension in cirrhotic patients. Objectives: To characterize cirrhotic population diagnosed by Fibroscan who are assisted in the Hepatology polyclinic of Hospital Pasteur. Material and Methods: Patients with diagnosis of liver cirrhosis of any etiology were studied, who have been assisted and monitored in the Hepatology polyclinic of Hospital Pasteur in the period 2015 - 2018. Results: 49 patients were included, of which 34 presented elements of portal hypertension. A higher prevalence of cirrhosis was found in men with alcoholic etiology and infection with hepatitis C virus. An association was found between Fibroscan values ≥ 15 kPa and the presence of portal hypertension. It was not possible to demonstrate a statistically significant association between Fibroscan values ≥ 15 kPa and the presence of gastric esophageal varices and/or gastropathy due to portal hypertension. Conclusions: The cut-off point used in Fibroscan is useful for the diagnosis of portal hypertension. It is necessary to continue performing fibrogastroscopy for the diagnosis of portal hypertension.

Resumo. Introdução: A hipertensão portal é uma síndrome comum nas doenças hepáticas crônicas. Dentre suas etiologias, destaca-se a cirrose hepática, responsável na grande maioria dos casos. Desde a incorporação da Elastografia de Transição (Fibroscan) no Uruguai, não foram realizados estudos nacionais que relacionem os resultados obtidos por essa técnica com a presença de PHT em pacientes cirróticos. Objetivo: Caracterizar a população cirrótica diagnosticada por Fibroscan atendida na Policlínica de Hepatologia do Hospital Pasteur. Material e Métodos: Foram estudados pacientes com diagnóstico de cirrose hepática de qualquer etiologia assistida e controlada na Policlínica de Hepatologia do Hospital Pasteur no período de 2015 a 2018. Resultados: Foram incluídos no estudo 49 pacientes, dos quais 34 apresentavam elementos de hipertensão portal foi encontrada maior prevalência de cirrose hepática em homens com etiologia alcoólica e infecção pelo vírus da hepatite C. Foi encontrada associação entre valores de Fibroscan ≥ 15 kPa e presença de hipertensão portal. Não foi possível demonstrar associação estatisticamente significante entre valores de Fibroscan ≥ 15 kPa e presença de varizes esofágicas gástricas e / ou gastropatia por hipertensão portal. Conclusões: O ponto de corte utilizado no Fibroscan é útil para o diagnóstico da hipertensão portal. É necessário continuar realizando fibrogastroscopia para o diagnóstico de hipertensão portal.

Association of Liver Histology with Sonological Grading and Liver Stiffness Measured by Fibroscan in Patients with NAFLD

Background: Non-alcoholic fatty liver disease (NAFLD) is theterm for a range of situations caused by a build-up of fat inthe liver. It's usually seen in people who are obese.Objective: In this study our main goal is to evaluate theassociation of liver histology with sonological grading and liverstiffness measured by Fibroscan in patients with NAFLD.Methods: This cross-sectional study was done at Departmentof Hepatology, Bangabandhu Sheikh Mujib Medical Universityfrom July 2007 to June 2009. Total 45 patients of fatty liverdisease were studied. All collected data was recorded in astructured questionnaire and was analyzed by SPSS version20. Values were expressed either as mean + SD or infrequency or in percentages.Results: During the study majority of the patients were 30-50years old (73.33 %), which indicates that the patients weresomewhat younger and out of 45 of study population 21(46.7%) patients was grade I fatty liver, 23(51.1%) were gradeII fatty liver and only one (2.2%) was grade III fatty liver. Thisstudy also showed that correlation between fibroscan of liverand grading of fibrosis in liver histology reveals significantassociation.

Evaluation of Noninvasive Liver Fibrosis Blood Markers in Patients with Chronic Hepatitis B and Hepatitis C

BACKGROUND: Liver fibrosis evaluation is an important issue in chronic liver disease patients. We aimed to develop noninvasive liver fibrosis biomarkers based on transient elastography (TE, FibroScan®) through retrospective review of clinicopathological data. METHODS: We recruited 278 chronic hepatitis B patients who underwent Fibroscan and HBV DNA testing. A total of 115 HBeAg-positive and 159 HBeAg-negative chronic hepatitis B patients were analyzed. A total of 100 hepatitis C patients were analyzed. Successful fibroscan data, gamma-glutamyl transferase (GGT) to platelet ratio (GPR), platelet count, AST, ALT, international normalized ratio of prothrombin time, total cholesterol, triglycerides, bilirubin, mean platelet volume, AST to platelet ratio index, fibrosis index based on four factors (FIB-4), neutrophil to lymphocyte ratio (NLR), and NLR to platelet ratio were analyzed to determine the new noninvasive markers for assessing liver fibrosis. RESULTS: Elevated GPR (OR=9.1, P=0.011) and FIB-4 (OR=2.3, P=0.01) were associated with greater risk of liver fibrosis in chronic hepatitis B patients. FIB-4 (OR=6.04, P=0.005) was a risk factor for liver fibrosis in HBeAg-positive patients. FIB-4 (OR=2.371, P=0.015) and GPR (OR=33.78, P=0.003) were liver fibrosis risk factor in HBeAg-negative patients. In chronic hepatitis C patients, GGT (OR=1.033, P=0.002), triglyceride (OR=−0.990, P=0.038) and FIB-4 (OR=3.499, P=0.006) showed statistical significances. The AUCs were 0.816 in FIB-4 (P<0.001) and 0.849 in GPR (P<0.001). CONCLUSIONS: FIB-4 and GPR may be useful blood markers for assessing liver fibrosis in chronic hepatitis B and hepatitis C patients. Further well-designed prospective study is required to validate these noninvasive blood markers in clinical practice.

Effect of simvastatin on the transforming growth factor β1, fibroscan scores, and aspartate transaminase to platelet index ratio patients with Liver Cirrhosis

Background: Cirrhosis of the liver is the liver disorder marked fibrosis and abnormal liver architecture. Treatment of liver cirrhosis, among others, is to reduce fibrogenesis. Simvastatin as an anti-fibrotic among others, by a mechanism reduce the activity of hepatic stellate cell of the liver, reduce cell proliferation liver stelat, increases the production of nitric oxide and decrease vascular resistance in the liver cirrhosis. Aim: This research to determine effect of simvastatin on the transforming growth factor β1, fibroscan scores, and aspartate transaminase to platelet index ratio patients with liver cirrhosis. Methods: This study is a randomized experiment, a sample of 30 people, divided into a control group given a placebo and the treatment given simvastatin 20 mg / day orally for 4 weeks. Before and after treatment measured levels of TGF β1, FibroScan score, and a score of APRI. Statistical analysis using SPSS 22 for windows. Two different test mean using parametric tests (independent t test, paired t test) and if the data is normally distributed variable or non-parametric tests (Mann-Whitney / Wilcoxon Signed Rank Test). P significant if p <0.05. Results: The results showed that the administration of simvastatin 20 mg for 4 weeks will reduce levels TGF β1 (20,98+7,80 µg/dl pretreatment, 16,20+5,50µg/dl post treatment; p=0,013), reduce fibroscan scores (22,29+14,65 kpa pretreatment, 13,61+4,02 kpa post treatment; p=0,049) and reduce APRI scores (40,13+41,28 pretreatment, 23,41+17,61 post treatment; p=0,002). Conclusion: This study demonstrated that administration Simvastatin will be reduced levels of the transforming growth factor β1, fibroscan scores, and aspartate transaminase to platelet index ratio patients with liver cirrhosis.

Rrelationship between liver volume atrophy rate,liver stiffness measurements and Child-Turcotte-Pugh value with Laennec histopathological classification in patients with hepatitis B cirrhosis / 重庆医学

Objective To explore the relationship between the liver volume atrophy rate,liver stiffness measurements(LSM) and Child-Turcotte-Pugh(CTP) value with the Laennec histopathological classification in the patients with hepatitis B cirrhosis and its value in the quantitative diagnosis of liver cirrhosis degree.Methods The clinicopathological data of liver biopsy tissue pathological slides,FibroScan,CT examination and hematological detection in 32 cases of hepatitis B cirrhosis were retrospectively analyzed.Liver cirrhosis was divided into mild,moderate and severe according to the Laennec liver cirrhosis histopathological classification.Then the relationship between the liver volume atrophy rate,LSM and CTP score with liver cirrhosis histopathological.Results Among 32 cases,9 cases(28.12％) were mild,12 cases(37.50％) were moderate and 11 cases(34.38％) were severe.The liver volume atrophy rates of mild,moderate and severe groups were (16.75±2.20)％,(23.11±6.67)％ and(35.55±5.70)％ respectively;LSM were(14.96±3.36),(20.21± 3.07),(37.03 ± 16.44) kPa respectively,the difference among 3 groups was statistically significant (P＜ 0.01).The CTP scores had no statistical difference among the 3 groups were(P＞0.05).The cirrhosis histopathological grade had the positive correlation with the liver volume atrophy rate and LSM(r=0.93,0.74,P＜0.01),however had no obvious correlation with the CTP scores(r=0.27,P＞0.05);the liver volume atrophy rate was positively correlated with LSM and CTP score(r=0.90,0.91,P＜0.01);while LSM had no obvious correlation with CTP score (r =0.15,P ＞ 0.05).Conclusion The more severe the cirrhosis histoathological grade,the bigger the liver volume atrophy rate and the higher the FibroScan detection value;the liver volume atrophy rate and LSM may serve as the quantitative diagnosis indicators of liver fibrosis histopathological severity.

Correlation between FibroScan, APRI Detecting the degree of esophageal and gastric varices of liver cirrhosis / 中华肝脏病杂志

Objective@#To investigate the predictive value of transient elastography (FibroScan), aspartate aminotransferase-to-platelet ratio index (APRI) in the detection of esophagogastric varices in patients with liver cirrhosis. @*Methods@#236 patients with liver cirrhosis who met the criteria were selected. All patients underwent gastroscopy. According to the degree of esophagogastric varices, patients were divided into four groups: none, mild, moderate, and severe. The patient's liver stiffness (LSM) and aspartate aminotransferase- to-platelet ratio index (APRI) were measured within 3 days of gastroscopy. One-way analysis of variance was used to compare multi-group data. The ROC curves of LSM, APRI, LSM+APRI in patients with liver cirrhosis with esophageal varices were plotted and their area under the ROC curve (AUC) were compared. @*Results@#The area under the ROC curve of LSM, APRI, LSM + APRI in patients with mild esophagogastric varices were 0.856, 0.900, and 0.906, respectively; moderate esophagogastric varices were 0.857, 0.924, and 0.923 respectively; and severe esophagogastric varices were 0.801, 0.903, and 0.901, respectively. @*Conclusion@#APRI and LSM+APRI have better predictive value for patients with cirrhosis who have esophagogastric varices.

Diagnostic value of two liver imaging techniques combined with serological models for hepatitis B virus-related liver fibrosis / 中华传染病杂志

Objective@#To compare the diagnostic efficacy of transient elastography (TE) FibroScan and acoustic radiation force impulse imaging (ARFI) combined with serological models including aspartate aminotransferase-to-platelet ratio (APRI) and fibrosis-4 (FIB-4) in hepatitis B virus-related fibrosis.@*Methods@#Sixty-seven patients with chronic HBV infection from October 2014 to May 2017 in Department of Infectious Diseases, Putuo Hospital were enrolled. Both FibroScan and ARFI were conducted in all patients together with serological tests. According to the golden standard of pathology results, the diagnosis values of FibroScan, ARFI combined with APRI or FIB-4 were compared as noninvasive assessment for liver fibrosis. Data with homogeneity of variance were tested by t test, and data with heterogeneity of variance were tested by Mann-Whitney U test.@*Results@#Based on the pathology results, the receiver operating characteristic (ROC) areas under the curve (AUC) of APRI, FIB-4, FibroScan and ARFI in diagnosis of hepatic fibrosis ≥S2 were 0.752, 0.612, 0.885, and 0.850, respectively. The AUC of ROC curve in diagnosis of hepatic fibrosis ≥S3 were 0.746, 0.733, 0.851, and 0.863, respectively. The AUC of ROC curve in diagnosis of hepatic fibrosis ≥S4 were 0.782, 0.705, 0.962 and 0.981, respectively. Combined liver imaging technique and serological tests, such as APRI with FibroScan, APRI with ARFI, FIB-4 with FibroScan or FIB-4 with ARFI, the AUC of ROC curve in the 4 groups in diagnosis of hepatic fibrosis ≥S2 were 0.887, 0.861, 0.893, and 0.853, respectively; in the diagnosis of hepatic fibrosis ≥S3 were 0.873, 0.871, 0.900, and 0.875, respectively; and in diagnosis of hepatic fibrosis ≥S4 were 0.952, 0.981, 0.969, and 0.981, respectively. FibroScan and ARFI were positively correlated with liver inflammation (r=0.467, P=0.000; r=0.371, P=0.002) and jaundice (r=0.424, P=0.000; r=0.0.312, P=0.01), while negatively correlated with platelet (r=-0.331, P=0.006; r=-0.312, P=0.01). The AUC of ROC curve of FibroScan, ARFI and their combination with serological model were significantly increased compared with the single serological model (all P<0.05).@*Conclusions@#Serological models such as APRI and FIB-4 as well as liver imaging techniques such as FibroScan and ARFI are all valuable in assessment of hepatic fibrosis, while FibroScan and ARFI have better diagnostic value. ARFI is convenient to application for its integration with the ordinary ultrasound system. The sensitivity and specificity for diagnosis of hepatic fibrosis could be improved by combining serological model with FibroScan or ARFI. Combination of APRI and ARFI show the highest accuracy in diagnosis of hepatic fibrosis. Combination of serological models and transient elastic liver imaging is recommended for assessment and follow-up of HBV-related fibrosis.

Comparison of FibroTouch and FibroScan for the assessment of fibrosis in chronic hepatitis B patients / 中华实验和临床病毒学杂志

Objective@#To explore the diagnostic values of FibroTouch and FibroScan for liver fibrosis in patients with chronic hepatitis B(CHB).@*Methods@#This study enrolled patients with CHB who was accepted liver biopsy at Beijing Friendship Hospital, Capital Medical University between March 2014 to December 2017. FibroTouch and FibroScan were performed among these patients at same time. Liver stiffness measurement(LSM), optimal cut-off value, receiver operating characteristic(ROC) were compared.@*Results@#In our 103 patients, there were no significantly different between FibroTouch and FibroScan in LSM. The threshold of the optimal cut-off value for FibroTouch and FibroScan were 5.45 versus 5.55 kPa (≥S1), 7.10 versus 6.65 kPa (≥S2), 11.05 versus 9.20 kPa (≥S3), 15.50 versus 15.45 kPa (S4), respectively. The area under the ROC curve for the prediction of the stage1, stage2, stage2, stage 4 of liver fibrosis in these patients were 0.858 versus 0.765 (P=0.54), 0.812 versus 0.801 (P=0.68), 0.863 versus 0.878 (P=0.45), and 1.0 versus 0.99 (P=0.38) respectively.@*Conclusions@#FibroTouch and FibmScan have a good consistency in the evaluation of the degree of liver fibrosis in patients with CHB.

Radiologic Evaluation of Non-Alcoholic Fatty Liver Disease in Diabetic Patient / 임상당뇨병

Non-alcoholic fatty liver disease (NAFLD), traditionally considered as a disease of hepatologists, has recently become a major concern in patients with type 2 diabetes mellitus (T2DM) as T2DM seems to worsen the course of NAFLD and vice versa. Furthermore, the increasing prevalence of NAFLD in T2DM and the complex mechanisms between these two diseases make physicians caring for patients with T2DM face many uncertainties in the diagnosis of NAFLD. Although the liver biopsy is considered as the gold standard of the diagnosis of NAFLD so far, it has several limitations such as infection, bleeding and cost. Hence, radiologic evaluations have been increasingly accepted as noninvasive alternatives to liver biopsy. Currently, 4 major imaging tools are available for measuring liver fat, including ultrasonography, computed tomography, magnetic resonance imaging and liver fibroscan. This article will describe these methods used to evaluate hepatic steatosis in patients with T2DM, including the diagnostic accuracy, limitations, and practical applicability.

Clinical effect of fuzhenghuayu capsule evaluated by liver instantaneous elastic imaging in treatment of early hepatocirrhosis / 中国医师进修杂志

Objective To estimate the clinical effect of fuzhenghuayu capsule in treatment of early hepatocirrhosis by liver instantaneous elastic imaging. Methods Eighty patients with early hepatocirrhosis were divided into experiment group and control group according to the treatment method with 40 cases each. All the patients in 2 groups were given the same antiviral treatment with entecavir dispersible tablets, and the patients in experiment group combined with fuzhenghuayu capsule. All treatment lasted for 6 months. The liver stiffness measurement (LSM) was measured before treatment and 1, 3 and 6 months after treatment by liver instantaneous elasticity imaging. The serum hyaluronic acid was measured, and the Child-Pugh score was evaluated at the same time. Results The LSM, hyaluronic acid and Child-Pugh scores 6 months after treatment in experiment group were significantly lower than those in control group:(19.3 ± 0.9) kPa vs. (29.6 ± 1.3) kPa, (215.6 ± 59.3)μg/L vs. (344.4 ± 39.6)μg/L and (2.1 ± 1.3) scores vs. (3.9 ± 0.9) scores, and there were statistical differences (P<0.05). No obvious adverse reactions related to the use of fuzhenghuayu capsule were found during the course of treatment. Conclusions Liver instantaneous elasticity imaging can be used to evaluate and monitor early hepatocirrhosis. Fuzhenghuayu capsule on patients with early hepatocirrhosis has a certain degree of curative effect.